Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07499544

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

Conditions: Chronic Hepatitis D Infection

Sex: All

Ages: 12 Years – 70 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 160

Sponsor: Huahui Health

Location: The First Hospital of Jilin University Changchun Jilin

Summary

This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.

Eligibility Criteria

Inclusion Criteria: * Willing to sign written informed consent; * Chronic HDV history with at least 6 months; * HDV RNA ≥500 IU/mL at screening; * ALT \>1ULN and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07499544). StuddyBuddy aggregates publicly available trial information.